PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes

Journal of Virology

Volumn 78, Issue 14, 2004, Pages 7602-7609

  Kawamura, Tatsuyoshi ^a   Bruce, Shannon E ^b   Abraha, Awet ^b   Sugaya, Makoto ^a   Hartley, Oliver ^c   Offord, Robin E ^c   Arts, Eric J ^b   Zimmerman, Peter A ^b   Blauvelt, Andrew ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AOP RANTES; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; NNY RANTES; PSC RANTES; RANTES; RANTES DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BINDING COMPETITION; CELL ISOLATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG POTENCY; EXPLANT; GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LANGERHANS CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEXUAL TRANSMISSION; T LYMPHOCYTE ACTIVATION; VIRUS INHIBITION; VIRUS ISOLATION;

ANTI-HIV AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COCULTURE TECHNIQUES; CULTURE TECHNIQUES; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LANGERHANS CELLS; POLYMORPHISM, GENETIC; RANTES; RECEPTORS, CCR5; SKIN;

EID: 3142749905     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.14.7602-7609.2004     Document Type: Article

References (46)

1. Ball, S. C., A. Abraha, K. R. Collins, A. J. Marozsan, H. Baird, M. E. Quinones-Mateu, A. Penn-Nicholson, M. Murray, N. Richard, M. Lobritz, P. A. Zimmerman, T. Kawamura, A. Blauvelt, and E. J. Arts. 2003. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77:1021-1038.
2. Bamshad, M. J., S. Mummidi, E. Gonzalez, S. S. Ahuja, D. M. Dunn, W. S. Watkins, S. Wooding, A. C. Stone, L. B. Jorde, R. B. Weiss, and S. K. Ahuja. 2002. A strong signature of balancing selection in the 5′ cis-regulatory region of CCR5. Proc. Natl. Acad. Sci. USA 99:10539-10544.
3. Carrington, M., and S. J. O'Brien. 2003. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54:535-551.
4. Dean, M., M. Carrington, C. Winkler, G. A. Huttley, M. W. Smith, R. Allikmets, J. J. Goedert, S. P. Buchbinder, E. Vittinghoff, E. Gomperts, S. Donfield, D. Vlahov, R. Kaslow, A. Saah, C. Rinaldo, R. Detels, and S. J. O'Brien. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-1862.
5. Fauci, A. S. 1999. The AIDS epidemic-considerations for the 21st century. N. Engl. J. Med. 341:1046-1050.
6. Flexner, C. W. 2003. Advances in HIV pharmacology: protein binding, pharmacogenomics, and therapeutic drug monitoring. Top. HIV Med. 11:40-44.
7. Gordon, C. J., M. A. Muesing, A. E. Proudfoot, C. A. Power, J. P. Moore, and A. Trkola. 1999. Enhancement of human immunodeficiency virus type 1 infection by the CC-chemokine RANTES is independent of the mechanism of virus-cell fusion. J. Virol. 73:684-694.
8. Guerin, S., L. Meyer, I. Theodorou, F. Boufassa, M. Magierowska, C. Goujard, C. Rouzioux, P. Debre, and J. F. Delfraissy. 2000. CCR5 delta32 deletion and response to highly active antiretroviral therapy in HIV-1-infected patients. AIDS 14:2788-2790.
9. Harrison, P. F., Z. Rosenberg, and J. Bowcut. 2003. Topical microbicides for disease prevention: status and challenges. Clin. Infect. Dis. 36:1290-1294.
10. Hartley, O., K. Dorgham, D. Perez-Bercoff, F. Cerini, A. Heimann, H. Gaertner, R. E. Offord, G. Pancino, P. Debre, and G. Gorochov. 2003. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines. J. Virol. 77:6637-6644.
11. Hu, J., M. B. Gardner, and C. J. Miller. 2000. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74:6087-6095.
12. Huang, Y., W. A. Paxton, S. M. Wolinsky, A. U. Neumann, L. Zhang, T. He, S. Kang, D. Ceradini, Z. Jin, K. Yazdanbakhsh, K. Kunstman, D. Erickson, E. Dragon, N. R. Landau, J. Phair, D. D. Ho, and R. A. Koup. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-1243.
13. Kahn, J. O., and B. D. Walker. 1998. Acute human immunodeficiency virus type 1 infection. N. Engl. J. Med. 339:33-39.
14. Kawamura, T., S. S. Cohen, D. L. Borris, E. A. Aquilino, S. Glushakova, L. B. Margolis, J. M. Orenstein, R. E. Offord, A. R. Neurath, and A. Blauvelt. 2000. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J. Exp. Med. 192:1491-1500.
15. Kawamura, T., F. O. Gulden, M. Sugaya, D. T. McNamara, D. L. Borris, M. M. Lederman, J. M. Orenstein, P. A. Zimmerman, and A. Blauvelt. 2003. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc. Natl. Acad. Sci. USA 100:8401-8406.
16. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
17. Mallal, S., D. Nolan, C. Witt, G. Masel, A. M. Martin, C. Moore, D. Sayer, A. Castley, C. Mamotte, D. Maxwell, I. James, and F. T. Christiansen. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732.
18. Marozsan, A. J., V. S. Torre, M. Johnson, S. C. Ball, J. V. Cross, D. J. Templeton, M. E. Quinones-Mateu, R. E. Offord, and E. J. Arts. 2001. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J. Virol. 75:8624-8638.
19. McComsey, G., D. J. Tan, M. Lederman, E. Wilson, and L. J. Wong. 2002. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 16:513-518.
20. McDermott, D. H., P. A. Zimmerman, F. Guignard, C. A. Kleeberger, S. F. Leitman, and P. M. Murphy. 1998. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 352:866-870.
21. Miller, C. J., and R. J. Shattock. 2003. Target cells in vaginal HIV transmission. Microbes Infect. 5:59-67.
22. Mosier, D. E., G. R. Picchio, R. J. Gulizia, R. Sabbe, P. Poignard, L. Picard, R. E. Offord, D. A. Thompson, and J. Wilken. 1999. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J. Virol. 73:3544-3550.
23. O'Brien, S. J., and J. P. Moore. 2000. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol. Rev. 177:99-111.
24. O'Brien, T. R., C. Winkler, M. Dean, J. A. E. Nelson, M. Carrington, N. L. Michael, and G. C. White. 1997. HIV-1 infection in a man homozygous for CCR5Δ32. Lancet 349:1219.
25. Pastore, C., G. R. Picchio, F. Galimi, R. Fish, O. Hartley, R. E. Offord, and D. E. Mosier. 2003. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES. Antimicrob. Agents Chemother. 47:509-517.
26. Pope, M., and A. T. Haase. 2003. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat. Med. 9:847-852.
27. Quinones-Mateu, M. E., S. C. Ball, A. J. Marozsan, V. S. Torre, J. L. Albright, G. Vanham, G. van Der Groen, R. L. Colebunders, and E. J. Arts. 2000. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 74:9222-9233.
28. Reece, J. C., A. J. Handley, E. J. Anstee, W. A. Morrison, S. M. Crowe, and P. U. Cameron. 1998. HIV-1 selection by epidermal dendritic cells during transmission across human skin. J. Exp. Med. 187:1623-1631.
29. Romani, N., S. Holzmann, C. H. Tripp, F. Koch, and P. Stoitzner. 2003. Langerhans cells-dendritic cells of the epidermis. APMIS 111:725-740.
30. Royce, R. A., A. Sena, W. Cates, and M. S. Cohen. 1997. Sexual transmission of HIV. N. Engl. J. Med. 336:1072-1078.
31. Rusconi, S., S. La Seta Catamancio, P. Citterio, E. Bulgheroni, F. Croce, S. H. Herrmann, R. E. Offord, M. Galli, and M. S. Hirsch. 2000. Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections. J. Virol. 74:9328-9332.
32. Sabbe, R., G. R. Picchio, C. Pastore, O. Chaloin, O. Hartley, R. Offord, and D. E. Mosier. 2001. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression. J. Virol. 75:661-671.
33. Salkowitz, J. R., S. E. Bruse, H. Meyerson, H. Valdez, D. E. Mosier, C. V. Harding, P. A. Zimmerman, and M. M. Lederman. 2003. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin. Immunol. 108:234-240.
34. Salkowitz, J. R., S. F. Purvis, H. Meyerson, P. Zimmerman, T. R. O'Brien, L. Aledort, M. E. Eyster, M. Hilgartner, C. Kessler, B. A. Konkle, G. C. White II, J. J. Goedert, and M. M. Lederman. 2001. Characterization of high-risk HIV-1 seronegative hemophiliacs. Clin. Immunol. 98:200-211.
35. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
36. Simmons, G., P. R. Clapham, L. Picard, R. E. Offord, M. M. Rosenkilde, T. W. Schwartz, R. Buser, T. N. C. Wells, and A. E. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276-279.
37. Smith, M. W., M. Dean, M. Carrington, C. Winkler, G. A. Huttley, D. A. Lomb, J. J. Goedert, T. R. O'Brien, L. P. Jacobson, R. Kaslow, S. Buchbinder, E. Vittinghoff, D. Vlahov, K. Hoots, M. W. Hilgartner, and S. J. O'Brien. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 277:959-965.
38. Torre, V. S., A. J. Marozsan, J. L. Albright, K. R. Collins, O. Hartley, R. E. Offord, M. E. Quinones-Mateu, and E. J. Arts. 2000. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J. Virol. 74:4868-4876.
39. Valdez, H., S. F. Purvis, M. M. Lederman, M. Fillingame, and P. A. Zimmerman. 1999. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy. JAMA 282:734.
40. van't Wout, A. B., N. A. Kootstra, G. A. Mulder-Kampinga, N. Albrecht-van Lent, H. J. Scherpbier, J. Veenstra, K. Boer, R. A. Coutinho, F. Miedema, and H. Schuitemaker. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J. Clin. Investig. 94:2060-2067.
41. Wilken, J., D. Hoover, D. A. Thompson, P. N. Barlow, H. McSparron, L. Picard, A. Wlodawer, J. Lubkowski, and S. B. Kent. 1999. Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES. Chem. Biol. 6:43-51.
42. Yamashita, T. E., J. P. Phair, A. Munoz, J. B. Margolick, R. Detels, S. J. O'Brien, J. W. Mellors, S. M. Wolinsky, and L. P. Jacobson. 2001. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 15:735-746.
43. Zaitseva, M., A. Blauvelt, S. Lee, C. K. Lapham, V. Klaus-Kovtun, H. Mostowski, J. Manischewitz, and H. Golding. 1997. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat. Med. 3:1369-1375.
44. Zhang, L. Q., P. MacKenzie, A. Cleland, E. C. H. J. Brown, and P. Simmonds. 1993. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J. Virol. 67:3345-3356.
45. Zhu, T., H. Mo, N. Wang, D. S. Nam, Y. Cao, R. A. Koup, and D. D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 261:1179-1181.
46. Zoeteweij, J. P., H. Golding, H. Mostowski, and A. Blauvelt. 1998. Cutting edge: cytokines regulate expression and function of the HIV coreceptor CXCR4 on human mature dendritic cells. J. Immunol. 161:3219-3223.